🎉 M&A multiples are live!
Check it out!

Herantis Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Herantis Pharma and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Herantis Pharma Overview

About Herantis Pharma

Herantis Pharma PLC is a biotech company developing disease-modifying therapies for Parkinson’s disease. The company's current development program focuses solely on HER-096, which is a peptidomimetic molecule designed to retain the biological activity of the neuroprotective CDNF protein.


Founded

2014

HQ

Finland
Employees

11

Website

herantis.com

Financials

LTM Revenue $11K

LTM EBITDA -$5.1M

EV

$35.2M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Herantis Pharma Financials

Herantis Pharma has a last 12-month revenue of $11K and a last 12-month EBITDA of -$5.1M.

In the most recent fiscal year, Herantis Pharma achieved revenue of n/a and an EBITDA of -$5.3M.

Herantis Pharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Herantis Pharma valuation multiples based on analyst estimates

Herantis Pharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA $0.3M -$5.3M XXX XXX XXX
EBITDA Margin Infinity% -Infinity% XXX XXX XXX
Net Profit -$10.0M $0.3M XXX XXX XXX
Net Margin -Infinity% Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Herantis Pharma Stock Performance

As of April 15, 2025, Herantis Pharma's stock price is EUR 1 (or $2).

Herantis Pharma has current market cap of EUR 34.9M (or $37.5M), and EV of EUR 32.8M (or $35.2M).

See Herantis Pharma trading valuation data

Herantis Pharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$35.2M $37.5M XXX XXX XXX XXX $-0.25

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Herantis Pharma Valuation Multiples

As of April 15, 2025, Herantis Pharma has market cap of $37.5M and EV of $35.2M.

Herantis Pharma's trades at 3281.4x LTM EV/Revenue multiple, and -6.9x LTM EBITDA.

Analysts estimate Herantis Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Herantis Pharma and 10K+ public comps

Herantis Pharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $35.2M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -6.6x XXX XXX XXX
P/E -7.1x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -5.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Herantis Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Herantis Pharma Valuation Multiples

Herantis Pharma's NTM/LTM revenue growth is n/a

Herantis Pharma's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.5M for the same period.

Over next 12 months, Herantis Pharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Herantis Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Herantis Pharma and other 10K+ public comps

Herantis Pharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -1742% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Herantis Pharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Herantis Pharma M&A and Investment Activity

Herantis Pharma acquired  XXX companies to date.

Last acquisition by Herantis Pharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . Herantis Pharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Herantis Pharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Herantis Pharma

When was Herantis Pharma founded? Herantis Pharma was founded in 2014.
Where is Herantis Pharma headquartered? Herantis Pharma is headquartered in Finland.
How many employees does Herantis Pharma have? As of today, Herantis Pharma has 11 employees.
Is Herantis Pharma publicy listed? Yes, Herantis Pharma is a public company listed on HEL.
What is the stock symbol of Herantis Pharma? Herantis Pharma trades under HRTIS ticker.
When did Herantis Pharma go public? Herantis Pharma went public in 2014.
Who are competitors of Herantis Pharma? Similar companies to Herantis Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Herantis Pharma? Herantis Pharma's current market cap is $37.5M
What is the current revenue of Herantis Pharma? Herantis Pharma's last 12-month revenue is $11K.
What is the current EBITDA of Herantis Pharma? Herantis Pharma's last 12-month EBITDA is -$5.1M.
What is the current EV/Revenue multiple of Herantis Pharma? Current revenue multiple of Herantis Pharma is 3281.4x.
What is the current EV/EBITDA multiple of Herantis Pharma? Current EBITDA multiple of Herantis Pharma is -6.9x.
Is Herantis Pharma profitable? Yes, Herantis Pharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.